Clinical staging of chronic lymphocytic leukemia
- PMID: 1139039
Clinical staging of chronic lymphocytic leukemia
Abstract
A method of clinical staging of chronic lymphocytic leukemia (CLL) has been proposed which is based on the concept that CLL is a disease of progressive accumulation of nonfunctioning lymphocytes: stage O, bone marrow and blood lymphocytosis only; stage 1, lymphocytosis with enlarged nodes; stage II, lymphocytosis with enlarged spleen or liver or both; stage III, lymphocytosis with anemia; and stage IV:lymphocytosis with thrombocytopenia. Analysis of 125 patients. in the present series showed the following median survival times (in months) from diagnosis: stage 0, is greater than 150; stage I 101; stage II, 71; stage III, 19; stage IV, 19, The median survival for the entire series was 71 mo. The prognostic significance of the stage remained even after adjustment was made for age and sex. However, both sex and age were shown to be poor predictors of survival after adjustment for stage. The method of staging proved to be a reliable predictor of survival whether used at diagnosis or during the course of the disease. The proposed staging system was an equally accurate indicator for survival when applied to two other previously published studies of large series of patients
Similar articles
-
Chronic lymphocytic leukaemia: a test of a proposed new clinical staging system.Scand J Haematol. 1981 Oct;27(4):279-86. doi: 10.1111/j.1600-0609.1981.tb00485.x. Scand J Haematol. 1981. PMID: 7346994
-
Chronic lymphocytic leukaemia: proposals for a revised prognostic staging system. Report from the International Workshop on CLL.Br J Haematol. 1981 Jul;48(3):365-7. doi: 10.1111/j.1365-2141.1981.tb02727.x. Br J Haematol. 1981. PMID: 7259986 No abstract available.
-
Multivariate analysis of prognostic factors in chronic lymphocytic leukemia.Isr J Med Sci. 1985 Jun;21(6):490-8. Isr J Med Sci. 1985. PMID: 4019142
-
Prognostic factors in chronic lymphocytic leukaemia and their implications for therapy.Clin Haematol. 1977 Feb;6(1):203-22. Clin Haematol. 1977. PMID: 334410 Review. No abstract available.
-
Cell kinetics in chronic lymphocytic leukaemia (CLL).Clin Haematol. 1977 Feb;6(1):159-67. Clin Haematol. 1977. PMID: 334407 Review.
Cited by
-
Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia.Cancers (Basel). 2020 Sep 23;12(10):2725. doi: 10.3390/cancers12102725. Cancers (Basel). 2020. PMID: 32977449 Free PMC article.
-
Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome.Cancers (Basel). 2022 Sep 25;14(19):4659. doi: 10.3390/cancers14194659. Cancers (Basel). 2022. PMID: 36230581 Free PMC article.
-
Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.Med Oncol. 2012 Dec;29(5):3561-9. doi: 10.1007/s12032-012-0262-4. Epub 2012 Jun 6. Med Oncol. 2012. PMID: 22669567
-
Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.Ann Hematol. 1991 Feb-Mar;62(2-3):54-8. doi: 10.1007/BF01714900. Ann Hematol. 1991. PMID: 2031968
-
Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression.Clin Exp Immunol. 1991 Jun;84(3):422-8. Clin Exp Immunol. 1991. PMID: 2044220 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical